‍

Daewoong Pet, a pet healthcare company, announced the release of 'Epicle', a pancreatic enzyme supplement designed for pets with exocrine pancreatic insufficiency, which makes it difficult for their pancreas to produce digestive enzymes. The product will be sold exclusively through animal hospitals, as announced on the 12th.

Epicle contains pancreatin, a digestive enzyme that aids in the digestion of starches, proteins, and fats, and lipase, a fat-digesting enzyme secreted only by the pancreas. This supplement helps improve digestive issues, nutrient absorption problems, and pancreatic pain caused by exocrine pancreatic insufficiency. It also helps resolve issues with steatorrhea (fatty stools) caused by undigested fat being expelled with the feces.

When pets suffer from chronic pancreatitis or exocrine pancreatic insufficiency (EPI), they experience a disruption in the pancreas's ability to secrete digestive enzymes. This results in difficulties in nutrient absorption and digestion.

Epicle is formulated as a fast-acting capsule, designed to quickly release its effects. It uses Daewoong Therapeutics' patented technology, combining alkaline stabilizers with digestive enzymes to neutralize stomach acid, ensuring optimal enzyme activity.

Lee Hyo-jun, CEO of Daewoong Pet, stated, "We will aggressively target the pet pancreatic enzyme supplement market in animal hospitals with Epicle at the forefront."